User login
In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.
Listen to the podcast below.
In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.
Listen to the podcast below.
In the final JCSO podcast for 2017, Dr David Henry, the Editor-in-Chief, discusses a round-up by Dr Linda Bosserman of cancer care in 2017 and an accompanying article on the therapeutic implications of some of the year’s landmark approvals. Continuing with the theme of therapeutic advances, he also highlights a review of the expanding treatment options for diverse neuroendocrine tumors. Two articles, one on setting up systems to facilitate adoption of the oncology care model in the practice setting and another on the clinical presentation, diagnosis, and management of bronchopulmonary carcinoid, provide evidence-based information and guidelines for practice-based oncology care teams. Patient and survivor care are the focus of three original research reports in which authors report on supportive medications and interventions received by prostate cancer survivors (PiCTure study); differences in psychosocial stressors between black and white cancer patients; and the impact of combining human and online supportive resources for prostate cancer patients. Also discussed are case reports on metastatic eccrine carcinoma with stomach and pericardial involvement and on cold hemolytic anemia as a rare complication of influenza A, as well as the approvals of pembrolizumab for dMMR/MSI-H tumors and brigatinib for crizotinib-resistant, ALK-positive NSCLC patients.
Listen to the podcast below.